dChan
Anonymous ID: d0aebf Aug. 15, 2024, 5:04 p.m. No.21419135   🗄️.is đź”—kun   >>9145 >>9165 >>9361 >>9565 >>9725 >>9788

>>21419111

anon's illness says so. it is obvious. anon wasn't retarded enough to get vaxxied and thats partially why anon hasn't been treated. Doctors hate anon, but keep anon alive. Just like to torture me multiple times a week to keep me alive enough to come back, but not alive enough to work.

 

Jokes on them. Anon spends the rest of the time here. The biggest mistake [THEY] ever made with anon, was keeping anon sick.

Anonymous ID: d0aebf Aug. 15, 2024, 5:51 p.m. No.21419501   🗄️.is đź”—kun

Hiding in Plain Sight: Interleukin-11 Emerges as a Master Regulator of Fibrosis, Tissue Integrity, and Stromal Inflammation

 

ABSTRACT

Interleukin (IL)-11 is upregulated in a wide variety of fibro-inflammatory diseases such as systemic sclerosis, rheumatoid arthritis, pulmonary fibrosis, inflammatory bowel disease, kidney disease, drug-induced liver injury, and nonalcoholic steatohepatitis. IL-11 is a member of the IL-6 cytokine family and has several distinct properties that define its unique and nonredundant roles in disease. The IL-11 receptor is highly expressed on stromal, epithelial and polarized cells, where noncanonical IL-11 signaling drives the three pathologies common to all fibro-inflammatory diseases—myofibroblast activation, parenchymal cell dysfunction, and inflammation—while also inhibiting tissue regeneration. This cytokine has been little studied, and publications on IL-11 peaked in the early 1990s, when it was largely misunderstood. Here we describe recent advances in our understanding of IL-11 biology, outline how misconceptions as to its function came about, and highlight the large potential of therapies targeting IL-11 signaling for treating human disease.